Oncotelic issues $0.75M in convertible notes at $0.07/sh; repays $307.5K Geneva Notes

Oncotelic Therapeutics, Inc.

Issued three convertible notes on Dec 9, 12, 15, 2021 totaling $0.75M gross; part of a $1.25M financing round.
Notes bear 12% interest, mature in one year, convertible at $0.07 per share; prepayment permitted with 3 days' notice.
Proceeds used for working capital, debt repayment, and payroll; restrictions on loans to officers/directors apply.
Fully repaid May and June 2021 Geneva Notes ($203,750 + $103,750) with interest and prepayment penalty.
JH Darbie & Co. receives 10% finder's fee in cash and warrants equal to 10% coverage at conversion price.

item 1.01 item 8.01 item 2.03 item 3.02 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.